Interestingly, tumor cell-derived proteins could affect the differentiation and function of DCs via the p38 MAPK pathway [30]; thus, we speculated that USP18 might affect DC-modulating immune responses through the MAPK pathway in the development of EN DLBCL. The gene discussed is USP18; the disease is diffuse large B-cell lymphoma.